Melanoma pathophysiology and drug targets

Emerging Therapeutics for Melanoma

Volumn , Issue , 2012, Pages 7-17

  Palmieri, Giuseppe ^a   Rozzo, Carla ^a   Gentilcore, Giusy ^b   Ascierto, Paolo Antonio ^b  

^a CNR   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882442590     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2217/EBO.11.29     Document Type: Chapter

References (37)

1. Curado MP, Edwards B, Shin HR et al. Cancer Incidence in Five Continents (Volume IX). International Agency for Research on Cancer (IARC) Scientific Publications, No 160, Lyon, France, (2007).
2. de Vries E, Coebergh JW. Melanoma incidence has risen in Europe. Br. Med. J. 331, 698 (2005).
3. Rigel DS. Epidemiology of melanoma. Semin. Cutan. Med. Surg. 29(4), 204-209 (2010).
4. Fortes C, Mastroeni S, Bakos L et al. Identifying individuals at high risk of melanoma: a simple tool. Eur. J. Cancer Prev. 19 (5), 393-400 (2010).
5. Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene 22, 3099-3112 (2003).
6. Miller AJ, Mihm MC. Melanoma. N. Engl. J. Med. 355, 51-65 (2006).
7. Palmieri G, Capone ME, Ascierto ML et al. Main roads to melanoma. J. Transl. Med. 7, 86 (2009).
8. Pho L, Grossman D, Laechman SA. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr. Opin. Oncol. 18, 173-192 (2006).
9. Meyle KD, Guldberg P. Genetic risk factors for melanoma. Hum. Genet. 126(4), 499-510 (2009).
10. Casula C, Muggiano A, Cossu A et al. Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer 9, 352 (2009).
11. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin. Cancer Res. 6(5), 1845-1853 (2000).
12. Box NF, Terzian T: The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res. 21, 525-533 (2008).
13. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 22, 3138-3152 (2003).
14. Giehl K. Oncogenic Ras in tumor progression and metastasis. Biol. Chem. 386, 193-205 (2005).
15. Heidorn SJ, Milagre C, Whittaker S et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140(2), 209-221 (2010).
16. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
17. Wellbrock C, Rana S, Paterson H et al. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS ONE 3, 2734 (2008).
18. Carreira S, Garraway LA, Widlund HR et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122 (2005).
19. Patton EE, Widlund HR, Kutok JL et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. 15, 249-254 (2005).
20. Michaloglou C, Vredeveld LC, Soengas MS et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724 (2005).
21. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat. Genet. 33(1), 19-20 (2003).
22. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer 95, 581-586 (2006).
23. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010)
24. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. (2011) (Epub ahead of print).
25. Kefford R, Arkenau H, Brown MP et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J. Clin. Oncol. 28(15 Suppl.), (2010) (Abstract 8503).
26. Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977 (2010).
27. Smalley KS, Sondak VK. Melanoma - an unlikely poster child for personalized cancer therapy. N. Engl. J. Med. 363, 876-878 (2010).
28. Wagle N, Emery C, Berger MF et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. (2011) (Epub ahead of print).
29. Johannessen CM, Boehm JS, Kim SY et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326), 968-972 (2010).
30. Villanueva J, Vultur A, Lee JT et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18 (6), 683-695 (2010).
31. Arcaro A, Guerreiro AS. The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr. Genomics 8, 271-306 (2007).
32. Ascierto PA, Streicher HZ, Sznol M. Melanoma: a model for testing new agents in combination therapies. J. Transl. Med. 8, 38 (2010).
33. Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melano cytic tumors based on DNA copy number changes. Am. J. Pathol. 163, 1765-1770 (2003).
34. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147 (2005).
35. Yeh I, Bastian BC. Genome-wide associations studies for melanoma and nevi. Pigment Cell Melanoma Res. 22(5), 527-528 (2009)
36. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
37. Infante JR, Falchook GS, Lawrence DP et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J. Clin. Oncol. 29(S), (2011) (Abstract CRA8503).